The effects of CYP2C9 and CYP2C19 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of glipizide in Chinese subjects

[1] Fuccella LM(1973)Metabolism and kinetics of the hypoglycemic agent glipizide in man — comparison with glibenclamide J Clin Pharmacol New Drug 13 68-75

[2] Tamassia V(1975)Comparison of the pharmacokinetics of glipizide and glibenclamide in man Eur J Clin Pharmacol 8 63-69

[3] Valzelli G(1999)Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele Pharmacogenetics 9 71-80

[4] Balant L(2007)Effects of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects FASEB J 21 lb362-958

[5] Fabre J(2002)Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 913-42

[6] Zahnd GR(1995)Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese Pharmacogenetics 5 37-15422

[7] Kidd RS(1994)The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 15419-598

[8] Straughn AB(1994)Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 594-1091

[9] Meyer MC(2007)Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry Acta Pharm Sin 42 1087-340

[10] Blaisdell J(2003)Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide Clin Pharmacol Ther 74 334-1270

[1] Fuccella LM(1973)Metabolism and kinetics of the hypoglycemic agent glipizide in man — comparison with glibenclamide J Clin Pharmacol New Drug 13 68-75

[2] Tamassia V(1975)Comparison of the pharmacokinetics of glipizide and glibenclamide in man Eur J Clin Pharmacol 8 63-69

[3] Valzelli G(1999)Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele Pharmacogenetics 9 71-80

[4] Balant L(2007)Effects of CYP2C9 genetic polymorphism on the pharmacokinetics and pharmacodynamics of glipizide in healthy Korean subjects FASEB J 21 lb362-958

[5] Fabre J(2002)Clinical significance of the cytochrome P450 2C19 genetic polymorphism Clin Pharmacokinet 41 913-42

[6] Zahnd GR(1995)Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese Pharmacogenetics 5 37-15422

[7] Kidd RS(1994)The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans J Biol Chem 269 15419-598

[8] Straughn AB(1994)Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese Mol Pharmacol 46 594-1091

[9] Meyer MC(2007)Simultaneous determination of metformin and glipizide in human plasma by liquid chromatography-tandem mass spectrometry Acta Pharm Sin 42 1087-340

[10] Blaisdell J(2003)Effect of rifampin on the pharmacokinetics and pharmacodynamics of gliclazide Clin Pharmacol Ther 74 334-1270